top of page

Enter for your chance to win a new Apple Watch Series 8.

Thank you for visiting the Canalevia-CA1 booth!

AppleWatch_Apps.png

Winner will be selected on January 25, 2023 and will be notified by email.

To learn more about Canalevia-CA1, click here.

Dog-34.png

BVD-002-0123

Enter Below

By clicking submit, you are agreeing to receive future communication about Canalevia®-CA1 from Jaguar Animal Health.

Thank you for participating!

Contact Us

 

1 (877) 787-3001

info@canalevia.com

  • Instagram
  • Facebook
  • LinkedIn

Location

 

Jaguar Animal Health

200 Pine Street, Suite 600

San Francisco, CA 94104

Canalevia_byJAG_Logo_White.png

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

IMPORTANT SAFETY INFORMATION

For oral use in dogs only. Not for use in humans. Keep Canalevia®-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

bottom of page